Skip to content
BHP

Research peptides in obesity: incretin, mitochondrial, and lipolytic approaches

Reviewed by the BestHealingPeptides Editorial Team ·

Obesity has become the pharmaceutical space with the most dramatic pharmacological progress of the 2020s, driven by the incretin peptide class. Semaglutide's ~15% weight-loss magnitude at Phase III (STEP trial programme) established the modern incretin era; tirzepatide's ~22% (SURMOUNT programme) and retatrutide's Phase II ~24% extended the effect-size trajectory further. Beyond the incretin approach, peptide research on obesity spans lipolytic (AOD-9604), mitochondrial-metabolic (MOTS-c AMPK activation), and NNMT-inhibitor (5-Amino-1MQ) pharmacology. Not all peptides in this space are licensed — the pharmacological toolkit for obesity research extends well beyond the currently licensed incretin medicines.

Retatrutide's Phase II ~24% weight-loss magnitude at 48 weeks approaches typical bariatric-surgery outcomes and represents the largest pharmacological weight-loss effect size documented to date. If Phase III (TRIUMPH programme) readouts confirm this magnitude, the pharmacological-vs-surgical efficacy gap for obesity treatment will have effectively closed for the highest-BMI populations where the additional weight-loss margin is clinically meaningful.

— Notable finding

Condition background

Obesity is defined by WHO as body mass index ≥30 kg/m² and is a chronic multi-factorial disease driven by complex genetic, endocrine, environmental, and behavioural contributors. UK prevalence estimates place adult obesity at approximately 28% (with an additional 36% overweight), producing substantial NHS burden through cardiovascular disease, type-2 diabetes, cancer, mechanical joint disease, and other complications. The pharmacological space historically underperformed relative to the disease burden — pre-2017 obesity medications produced modest weight loss (<10%) with unattractive risk-benefit profiles. Landmark shifts followed with GLP-1 receptor agonist development for type-2 diabetes producing weight-loss magnitudes that motivated obesity-specific development (semaglutide 2.4 mg weekly as Wegovy, FDA-approved 2021). Bariatric surgery remains the highest-efficacy intervention (typical 25-35% weight loss maintained at 5+ years) but is invasive and access-limited. The modern incretin class narrows the pharmacology-vs-surgery efficacy gap substantially.

Current treatment landscape

Current UK NHS obesity treatment follows NICE guidance with lifestyle intervention as first-line, followed by pharmacological intervention where BMI thresholds and co-morbidity criteria are met. Semaglutide (Wegovy) is NHS-available for eligible patients through specialist weight-management services; tirzepatide (Mounjaro) has received UK licensing for weight management with NHS access under similar specialist-service pathways. Bariatric surgery is available on the NHS for eligible patients failing pharmacological and lifestyle intervention with BMI ≥40 (or ≥35 with co-morbidities). Private prescription of semaglutide and tirzepatide is widely available at cost. Orlistat (Xenical, alli) remains available for pharmacy sale with modest efficacy. Retatrutide is not yet licensed and remains investigational pending TRIUMPH Phase III readouts (expected 2026-2027).

Why peptides are studied here

Multiple pharmacological approaches to obesity are represented in peptide research. The incretin approach engages GLP-1, GIP, and glucagon receptors to drive appetite suppression, glucose-dependent insulin release, delayed gastric emptying, and (for glucagon co-agonists) increased resting energy expenditure. [Semaglutide](/peptides/semaglutide) is the GLP-1 monoagonist that established the class; [tirzepatide](/peptides/tirzepatide) is the GLP-1/GIP dual-agonist extending effect size; [retatrutide](/peptides/retatrutide) is the Phase III GLP-1/GIP/glucagon triple-agonist producing the largest weight-loss magnitudes documented for any pharmacological approach. The mitochondrial-metabolic approach engages AMPK activation and mitochondrial biogenesis through [MOTS-c](/peptides/mots-c) — a mitochondrial-derived peptide with metabolic-regulatory effects distinct from the incretin pathway. The lipolytic approach engages GH-fragment pharmacology through [AOD-9604](/peptides/aod-9604) — a synthetic fragment of the C-terminal GH region originally developed as an oral obesity medication with modest efficacy. The NNMT-inhibitor approach engages NAD⁺-elevation and metabolic-flexibility pharmacology through [5-Amino-1MQ](/peptides/5-amino-1mq) — a small-molecule NNMT inhibitor with obesity-metabolism research applications. These approaches are broadly complementary rather than competitive; the incretin class currently dominates clinical efficacy magnitudes.

Relevant research peptides

Notable study findings

  • Semaglutide (STEP trial programme)

    STEP-1 (Wilding et al., NEJM 2021) documented mean weight loss of approximately 15% body weight at 68 weeks on 2.4 mg weekly semaglutide versus 2.4% on placebo, establishing the modern incretin weight-loss paradigm and supporting FDA/EMA/MHRA registration of Wegovy for obesity.

  • Tirzepatide (SURMOUNT trial programme)

    SURMOUNT-1 (Jastreboff et al., NEJM 2022) documented mean weight loss of approximately 22.5% body weight at 72 weeks on 15 mg weekly tirzepatide versus 2.4% on placebo — extending the incretin-class effect size beyond semaglutide and supporting registration.

  • Retatrutide (Phase II)

    Retatrutide Phase II obesity trial (Jastreboff et al., NEJM 2023) documented mean weight loss of approximately 24% body weight at 48 weeks on 12 mg weekly — the largest pharmacological weight-loss magnitude documented to date, approaching bariatric-surgery outcomes.

  • MOTS-c (pre-clinical metabolic effects)

    MOTS-c administration in rodent obesity models produces AMPK activation, improved insulin sensitivity, reduced adiposity, and improved metabolic flexibility — supporting the mitochondrial-metabolic research application distinct from the incretin pathway.

Relevant research stacks

UK regulatory notes

Semaglutide and tirzepatide are MHRA-licensed for weight management with NHS access under specialist-service pathways; private prescription is widely available. Retatrutide is not yet licensed anywhere and remains investigational — grey-market retatrutide supply has emerged ahead of licensing and MHRA has issued warnings. AOD-9604 is not licensed as a medicine in any jurisdiction. MOTS-c is not licensed and is on the WADA Prohibited List (S2) given exercise-endurance-enhancement effects. 5-Amino-1MQ is not licensed and remains a research compound. Athletes should note that all these compounds are either explicitly WADA-prohibited (semaglutide/tirzepatide/retatrutide/MOTS-c under S2) or plausibly captured by broader anti-doping frameworks.

Frequently asked questions

How does the incretin approach differ from earlier obesity medications?
Earlier obesity medications (orlistat, phentermine/topiramate, naltrexone/bupropion, lorcaserin) produced modest weight loss (<10%) through disparate mechanisms with unattractive risk-benefit profiles. The incretin class produces substantially larger weight loss (15-24% at Phase II/III trial time-points) through GLP-1 (and GIP, glucagon) receptor pharmacology with generally acceptable safety profiles, fundamentally changing the pharmacological-vs-surgical treatment landscape for obesity.
What is the difference between semaglutide, tirzepatide, and retatrutide?
All three target the incretin pathway but with progressively broader receptor coverage. Semaglutide is a GLP-1 monoagonist; tirzepatide is a GLP-1/GIP dual-agonist; retatrutide is a GLP-1/GIP/glucagon triple-agonist. Weight-loss magnitude increases with receptor coverage — from ~15% (semaglutide, Phase III) to ~22% (tirzepatide, Phase III) to ~24% (retatrutide, Phase II). Semaglutide and tirzepatide are MHRA-licensed; retatrutide is investigational pending Phase III readouts.
Is MOTS-c an alternative to incretin therapy?
MOTS-c and the incretin class engage fundamentally different pharmacological pathways — MOTS-c through mitochondrial-AMPK activation, the incretins through central appetite suppression and glucose-dependent insulin regulation. Clinical efficacy magnitudes for MOTS-c in obesity contexts have not been characterised at the scale of the incretin trials, and MOTS-c remains a research compound rather than clinical medicine. The two approaches are broadly complementary rather than substitutive.
What are the safety concerns with incretin weight-loss medications?
Gastrointestinal adverse events (nausea, vomiting, diarrhoea) predominate and are dose-related; dose-titration mitigates severity. Pancreatitis and biliary disease are documented but uncommon. Retinopathy in diabetic populations, gallbladder disease, and (theoretical concern) medullary thyroid cancer are considerations informing prescribing labels. Weight regain after discontinuation is characteristic — the treatments require sustained use rather than being curative. Long-term (10+ year) safety data are still accumulating.
Can retatrutide be accessed in the UK?
Retatrutide is not yet MHRA-licensed and access is restricted to clinical trial participation. Grey-market retatrutide supply has emerged in research-chemical channels ahead of licensing; this supply is unauthorised, MHRA has issued warnings, and product quality and safety cannot be verified. Waiting for licensed access is strongly preferable to grey-market use given the safety and regulatory considerations.
How does bariatric surgery compare with modern incretin therapy?
Bariatric surgery remains the highest-efficacy obesity intervention with typical 25-35% weight loss maintained at 5+ years — outcomes not consistently matched by pharmacological approaches even with retatrutide. However, surgery is invasive, has surgical risks, and has access limitations. Modern incretin therapy (semaglutide, tirzepatide, retatrutide) narrows the efficacy gap substantially and is a valid pharmacological alternative for many patients. Combined pharmacological-and-surgical strategies are also an active clinical research area.
What lifestyle intervention is expected alongside incretin therapy?
Clinical trials of incretin weight-loss medications typically include lifestyle intervention (caloric reduction, physical activity, behavioural counselling) as concurrent standard-of-care. Trial weight-loss magnitudes reflect combined pharmacological-plus-lifestyle effects. UK NHS obesity pathways similarly integrate pharmacological intervention with structured lifestyle support delivered through specialist weight-management services.

Where to source research peptides for laboratory research

The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.

  • PeptideAuthority.co.uk

    UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.

  • PeptideBarn.co.uk

    Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.